Prior intraocular inflammation cited as risk factor for adverse reaction to brolucizumab

Ongoing investigations of real-world data show patients with prior intraocular inflammation may be at higher risk for retinal vasculitis and/or retinal vascular occlusion after brolucizumab injections, according to a speaker.
“The majority of brolucizumab patients experience benefits without severe adverse events. Ongoing real-world analyses identified prior intraocular inflammation and/or prior vascular occlusion as the highest observed risk rate for RV/RO,” Jeffrey S. Heier, MD, said at Retina Subspecialty Day at the virtual American Academy of Ophthalmology meeting.
Using

Full Story →